dc.contributor.author | Nieder, Carsten | |
dc.contributor.author | Johnsen, Silje Kristine | |
dc.contributor.author | Winther, Annette M. | |
dc.contributor.author | Mannsåker, Bård | |
dc.date.accessioned | 2024-10-04T11:54:44Z | |
dc.date.available | 2024-10-04T11:54:44Z | |
dc.date.issued | 2024-03-26 | |
dc.description.abstract | Background Multimodal breast cancer treatment may cause side effects reflected in patient-reported outcomes and/or
symptom scores at the time of treatment planning for adjuvant radiotherapy. In our department, all patients have been
assessed with the Edmonton Symptom Assessment System (ESAS; a questionnaire addressing 11 major symptoms and
wellbeing on a numeric scale of 0–10) at the time of treatment planning since 2016. In this study, we analyzed ESAS
symptom severity before locoregional radiotherapy.<p>
<p>Patients and methods Retrospective review of 132 patients treated between 2016 and 2021 (all comers in breast-conserving
or post-mastectomy settings, different radiotherapy fractionations) was performed. All ESAS items and the ESAS point
sum were analyzed to identify subgroups with higher symptom burden and thus need for additional care measures.
<p>Results The biggest patient-reported issues were fatigue, pain, and sleep problems. Patients with triple negative breast
cancer reported a higher symptom burden (mean 30 versus 20, p= 0.038). Patients assigned to adjuvant endocrine therapy
had the lowest point sum (mean 18), followed by those on Her-2-targeting agents without chemotherapy (mean 19), those
on chemotherapy with or without other drugs (mean 26), and those without systemic therapy (mean 41), p= 0.007. Those
with pathologic complete response after neoadjuvant treatment had significantly lower anxiety scores (mean 0.7 versus 1.8,
p= 0.03) and a trend towards lower depression scores, p= 0.09.
<p>Conclusion Different surgical strategies, age, and body mass index did not impact on ESAS scores, while the type of
adjuvant systemic therapy did. The effect of previous neoadjuvant treatment and unfavorable tumor biology (triple negative)
emerged as important factors associated with symptom burden, albeit in different domains. ESAS data may facilitate
identification of patients who should be considered for additional supportive measures to alleviate specific symptoms. | en_US |
dc.identifier.citation | Nieder, Johnsen, Winther, Mannsåker. Patient-reported symptoms before adjuvant locoregional radiotherapy for breast cancer: triple-negative histology impacts the symptom burden. Strahlentherapie und Onkologie (Print). 2024 | en_US |
dc.identifier.cristinID | FRIDAID 2259891 | |
dc.identifier.doi | 10.1007/s00066-024-02224-8 | |
dc.identifier.issn | 0179-7158 | |
dc.identifier.issn | 1439-099X | |
dc.identifier.uri | https://hdl.handle.net/10037/35061 | |
dc.language.iso | eng | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.journal | Strahlentherapie und Onkologie (Print) | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2024 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Patient-reported symptoms before adjuvant locoregional radiotherapy for breast cancer: triple-negative histology impacts the symptom burden | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |